ImmunoPrecise Antibodies (IPA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Benchmark Co. Maintains ImmunoPrecise Antibodies(IPA.US) With Buy Rating, Cuts Target Price to $3
Moomoo NewsAug 15 03:31 ET · Ratings
Express News | Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3
BenzingaAug 14 13:32 ET
Express News | Immunoprecise Antibodies Ltd : Benchmark Cuts Target Price to $3
ReutersAug 13 11:08 ET
Express News | HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target
BenzingaJul 30 06:46 ET
ImmunoPrecise Antibodies Analyst Ratings
BenzingaJul 30 06:45 ET · Ratings
Express News | ImmunoPrecise Antibodies Q4 Loss Of C$(18.05)M Compared To C$(5.13)M A Year Ago
BenzingaJul 29 08:55 ET

Comments

Trytosaveabit

Aug 15 13:22

This is for you if you’re paying attention? Hehehe.

$ImmunoPrecise Antibodies (IPA.US)$ Yes im always looking for them “ Bouncing Cats “ Hehehe! Well here is a cat that bounced on Tuesday and is still moving up! And this is why im always looking for a DCB! Hehehe! Sure hope you see this post? Otherwise it would be totally different! Hehehe! BTW again nice having you around so much this week🤭🤣

1

4

Jaguar8

Jul 17 00:33

NEWS

$ImmunoPrecise Antibodies (IPA.US)$
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
ImmunoPrecise Antibodies (IPA) has entered into a $3.0 million convertible debenture agreement with Yorkville Advisors Global, LP. The deal includes two tranches: $2.0 million completed on July 16, 2024, and $1.0 million pending SEC approval. Key features:
- 8.0% annual interest rate
- Convertible to comm...

1

Jaguar8

Jun 25 06:28

NEWS

$ImmunoPrecise Antibodies (IPA.US)$
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
ImmunoPrecise Antibodies (IPA) announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI to develop an AI model for pharmacogenomics, leveraging BioStrand's LENSai technology. This partnership aims to enhance precision medicine by integrating AI with vast genomic data to improve pa...

Stock Region

Jun 11 10:22

Biotherapeutic Technology Company Announces Commercial Offering For AI-Driven Drug Discovery

ImmunoPrecise Antibodies Subsidiary BioStrand Announces Immediate Commercial Offering Of Software With Customizable Interface For AI-Driven Drug Discovery.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution,...

Trytosaveabit

Jun 10 06:18

Update

$ImmunoPrecise Antibodies (IPA.US)$ Reuters· 1 min ago
Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery

4

IPA ImmunoPrecise Antibodies

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target